OC.11.2 RAFOXANIDE INHIBITS EPITHELIAL STAT3 ACTIVATION AND STAT3-DRIVEN ONCOGENIC IMMUNE RESPONSE IN THE COLORECTAL CANCER MICROENVIRONMENT. (March 2023)